Researchers at Mount Sinai launch a new AI platform to match more cancer patients with clinical trials, aiming to expand ...
Over the past several years, pharmaceutical companies have been steadily integrating artificial intelligence (AI) into many aspects of clinical development. Today, AI’s impact is being felt from the ...
2. Trial visits are kept to a minimum with potential utilization of telemedicine or stipends increase attendance 3. Trial mimics typical clinical workflow with minimization of visits, and laboratory ...
Despite rapid growth, only 9.2% of DCTs are multiregional and over 80% single-country, indicating challenges in international implementation. 2 With regulatory agencies 4–7 underscoring risk-based ...
The integration of artificial intelligence (AI) and machine learning (ML) in oncology clinical trials is rapidly evolving alongside the broader field. For example, AI-driven adaptive trial designs may ...
Psyence BioMed Announces Approval for Use of PsyLabs’ Psilocybin Product in Phase IIb Clinical Trial
NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies ...
Valerie M. Harvey, MD, MPH, FAAD, founder of the Hampton Roads Center for Dermatology, highlighted the long-standing underrepresentation of minority populations in dermatology clinical trials at the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results